Overview of the SPRING Trial and LHP588
Lighthouse Pharmaceuticals, a Novato, California-based clinical-stage biopharmaceutical company, is poised to share new data from its Phase 2 SPRING trial of LHP588, a next-generation gingipain inhibitor designed to address P. gingivalis-positive Alzheimer’s disease. Gingipains are enzymes produced by the oral bacterium Porphyromonas gingivalis, which researchers have linked to inflammatory pathways implicated in neurodegeneration. The upcoming CTAD 2025 poster presentation highlights the company’s focused approach to precision medicine by targeting a microbial factor believed to contribute to cognitive decline.
The Scientific Context
Emerging science connects chronic oral infections to Alzheimer’s disease through mechanisms involving gingipains. LHP588 is developed to selectively inhibit these proteases, with the aim of reducing neuroinflammation and slowing disease progression in patients with evidence of P. gingivalis involvement. While prior studies have explored gingipain inhibition, LHP588 represents a next-generation design intended to improve pharmacodynamic and safety profiles, potentially expanding treatment options for a subset of patients with Alzheimer’s disease who test positive for Porphyromonas gingivalis markers.
What to Expect at CTAD 2025
The poster at the Clinical Trials on Alzheimer’s Disease (CTAD) conference will present Phase 2 SPRING trial design, interim efficacy signals, safety data, and biomarker readouts relevant to gingipain inhibition. Attendees will gain insights into how LHP588 performs in the target patient population and how the therapy may interact with existing standard-of-care approaches. Lighthouse emphasizes rigorous trial methodology, including patient selection criteria that if replicated could inform future precision medicine strategies in Alzheimer’s disease research.
Trial Design and Endpoints
Details expected to be shared include the SPRING trial’s randomization structure, dosing regimens, and primary endpoints related to cognitive and functional outcomes. Secondary endpoints may cover biomarker changes associated with gingipain activity, neuroinflammation markers, and imaging indicators of disease modification. By focusing on P. gingivalis-positive patients, the study aims to clarify whether targeting this microbial pathway translates into measurable clinical benefit and safety in a well-defined cohort.
Clinical Implications and Future Directions
If the SPRING trial demonstrates favorable signals, LHP588 could advance into larger pivotal studies or pave the way for companion diagnostic development to identify eligible patients more efficiently. The broader implication is a shift toward microbe-targeted therapies in Alzheimer’s disease research, where precision medicine approaches seek to tailor treatments based on individual microbial and biomarker profiles. Lighthouse remains committed to transparent disclosure of trial data and ongoing collaboration with academic and industry partners to validate the gingipain hypothesis in neurodegenerative disease.
About Lighthouse Pharmaceuticals
Headquartered in Northern California, Lighthouse Pharmaceuticals specializes in precision medicine approaches to complex diseases with high unmet medical needs. The company’s pipeline emphasizes targeted interventions designed to improve outcomes for patient populations that benefit most from biomarker-guided therapies. The CTAD 2025 poster underscores Lighthouse’s ongoing efforts to translate emerging neuroscience and microbiology insights into clinically meaningful treatments.
Conference Details
CTAD 2025 serves as a leading forum for researchers and clinicians to discuss breakthroughs in Alzheimer’s disease and related dementias. Lighthouse’s poster presentation will provide conference attendees with a concise synthesis of SPRING trial objectives, interim findings, and the potential clinical relevance of LHP588 as a next-generation gingipain inhibitor.
